SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer

PURPOSE: Cixutumumab, formerly IMC-A12, is a recombinant human monoclonal immunoglobulin G(1) antibody that targets insulin-like growth factor I receptor (IGF-IR). Cixutumumab was synergistic with castration in a hormone-sensitive prostate cancer xenograft model. PATIENTS AND METHODS: Patients with...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Oncol
Main Authors: Yu, Evan Y., Li, Hongli, Higano, Celestia S., Agarwal, Neeraj, Pal, Sumanta K., Alva, Ajjai, Heath, Elisabeth I., Lam, Elaine T., Gupta, Shilpa, Lilly, Michael B., Inoue, Yoshio, Chi, Kim N., Vogelzang, Nicholas J., Quinn, David I., Cheng, Heather H., Plymate, Stephen R., Hussain, Maha, Tangen, Catherine M., Thompson, Ian M.
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2015
Subjects:
ORIGINAL REPORTS
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4417730/
https://ncbi.nlm.nih.gov/pubmed/25847934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.59.4127
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items